Ivermectin and vitamin C doses were proposed by several friends as a cure for my wife’s cancer instead of traditional radiation and chemotherapy. My problem with these friends is that the oncologist said she’d be dead in six weeks if we didn’t start both immediately. Now, are you going to trust friends over facts. I’m not. Kill your own loved ones if you want. She’s making remarkable progress now. I trust doctors over conjecture and my cousin knows a guy.. To each his own of course, but trusting rumors over facts has consequences. Not just IMO
From the Linus Paulding Institute web site at Oregon State University. Linus Paulding is the guy who first came up with the idea that high dose vitamin C could prevent or lessen the effects of colds:
Regular supplementation with vitamin C (0.25 to 2 g/day) did not reduce the incidence of colds in the general population (23 trials); however, in participants undergoing heavy physical stress (e.g., marathon runners, skiers, or soldiers in subarctic conditions), vitamin C supplementation halved the incidence of colds (5 trials). A benefit of regular vitamin C supplementation was also seen in the duration of colds, with a greater benefit in children than in adults: The pooled effect of vitamin C supplementation was a 14% reduction in cold duration in children and an 8% reduction in adults. Finally, no significant effect of vitamin C supplementation (1-8 g/day) was observed in therapeutic trials in which vitamin C was administered after cold symptoms occurred.
Note, that it halved the incidence in a very specific subset of people, marathon runners, skiers, and soldiers in subarctic conditions. For normal people there is no effect. And it has to be taken continually. An 8% reduction in the duration of a cold that last 7-10 days untreated is clinically meaningless.
Your specific claim was a cure of cancer...
Current evidence from controlled clinical trials indicates that intravenous vitamin C is generally safe and well tolerated in cancer patients. Of note, because intravenous administration of 80 g of vitamin C precipitated hemolytic anemia in two subjects with glucose-6-phosphate dehydrogenase deficiency, patients due to receive high-dose vitamin C infusion are systematically screened for this genetic disorder (166).
Retrospective in vitro colony formation assays revealed that patient leukemic cells displayed variable sensitivity to vitamin C treatment: leukemic cells from seven out of the nine patients who experienced a significant clinical benefit were sensitive to vitamin C in vitro (i.e., "responders"); the leukemic cells from the remaining six patients were not sensitive to vitamin C (i.e., "non-responders"). Thus, in vitro vitamin C sensitivity assays may provide predictive value for the clinical response to intravenous vitamin C treatment. The mechanisms underlying differential sensitivity to vitamin C are under investigation. In vitro experiments performed using 11 different cancer cell lines demonstrated that sensitivity to vitamin C correlated with the expression of catalase, an enzyme involved in the decomposition of hydrogen peroxide (172). Approximately one-half of the cell lines tested were resistant to vitamin C cytotoxicity, a response associated with high levels of catalase activity.
Sensitivity to vitamin C may also be determined by the expression of sodium-dependent vitamin C transporter-2 (SVCT-2), which transports vitamin C into cells (173). Higher SVCT-2 levels were associated with enhanced sensitivity to vitamin C in nine different breast cancer cell lines. Moreover, SVCT-2 was significantly expressed in 20 breast cancer tissue samples, but weakly expressed in normal tissues. Finally, mutations in genes coding for vitamin C-dependent TET demethylases, mutations that are common in cancer cells, may also contribute to resistance to vitamin C treatment (165).
Efficacy
A recent phase II clinical trial in 34 patients with stage IV (metastatic) pancreatic cancer found that adding intravenous vitamin C (75 g in a two-hour infusion three times weekly) to standard of care chemotherapy extended progression-free survival (6.2 months compared to 3.9 months) and nearly doubled overall survival (16 months vs. 8.3 months) (209). Despite these encouraging findings, most evidence on the efficacy of intravenous vitamin C in cancer patients is limited to observational studies, uncontrolled interventions, and case reports (174, 175). Thus, there is a need for more extensive, longer-duration phase II clinical trials that test the efficacy of intravenous vitamin C in disease progression and overall survival, especially against various types of cancer (176).
m.economictimes.com
www.cbsnews.com
